NS-2330
Tesofensine is a small-molecule monoamine reuptake inhibitor (norepinephrine, serotonin, dopamine triple reuptake inhibitor / SNRI+DRI). Originally developed by NeuroSearch for Parkinson's disease and Alzheimer's disease, repurposed for obesity after Phase 2 trials showed substantial weight loss as an off-target effect. The TIPO-1 trial in obese patients showed dose-dependent weight loss up to ~12% at 1mg daily over 24 weeks - among the largest non-injectable weight loss agents.
Morning preferred (CNS-active).
Start here. Every protocol below is ordered lowest-first. Begin at the smallest effective dose, hold about a week to assess tolerance, and step up only if needed.
Tesofensine is a triple monoamine reuptake inhibitor:
Increases synaptic NE - drives sympathetic activation, energy expenditure, and appetite suppression.
Increases synaptic DA in reward and appetite circuits - reduces hedonic feeding drive.
Modest 5-HT effect contributes to appetite suppression and satiety.
Substantial appetite reduction + modest energy expenditure increase = up to 12% weight loss at 1mg daily in TIPO-1 trial.
NE/DA reuptake inhibition raises HR and BP - dose-limiting at higher doses. Tesomet combination with metoprolol (beta-blocker) mitigates this in Mexican formulation.
Insomnia, dry mouth, nausea, anxiety - all class-typical for triple reuptake inhibitors.
Days 1-7: rapid appetite suppression onset.
Weeks 4-12: peak weight loss (up to ~12% at 1mg).
Long-term: efficacy beyond 24 weeks not well characterized.
Each reference below was re-fetched from its PubMed record, and the quoted sentence was confirmed to appear in that abstract and to support the claim it sits under. Follow any of them to read the source.
Exact-molecule evidence boundary: the live abstract reports the quoted finding for Tesofensine; no broader inference is made.
We assessed the efficacy and safety of tesofensine-an inhibitor of the presynaptic uptake of noradrenaline, dopamine, and serotonin-in patients with obesity.
Evidence scope. Exact molecule wording appears in the quoted live sentence. Only the population/model, formulation, route, and outcome expressly stated there are supported.
Claims we could not support
No abstract we checked supports these for this molecule at this route. That is not the same as saying they are false — it marks where the evidence is missing.
Dose/route: 0.25mg daily; Oral capsule; 1x daily. No selected live abstract sentence verified this complete regimen.
Mechanism as written in source JSON. No selected live abstract sentence verified the complete mechanism at the card formulation/route and relevant population/model.
Primary safety claim as written in source JSON. No selected live abstract sentence verified the complete safety claim for this exact formulation and route.
Long
Post-ingestion
Steady state achieved over weeks
Oral high (~90%)
Daily dosing maintains steady state
Hepatic
Storage. Capsule. Cool dry location.
Approved in Mexico (Tesomet, 2023) for obesity and Prader-Willi syndrome. NOT FDA-approved. Available outside Mexico as research chemical.
Put it to work
Open Tesofensine straight into OnePin with your vial and dose pre-filled, then let it handle the syringe math and remind you before the vial runs out.
Open Tesofensine in the app →Go deeper
The complete Tesofensine walkthrough, real protocol discussion and coaching live inside the BlessUp community on Skool.
Join the community ↗Track it in OnePin. Log vials, draws, and protocols in the app.
Type a name, brand, or tool. Esc closes.